Skip to main content
OpenTrials
Completed

NCT Number: NCT00667927

Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission

This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

About this study

The primary objective of this study was to estimate the continuous complete remission rate at 2 years post transplant for children with AML in first complete remission treated with autologous BMT.

Secondary objectives used transduction of marker genes into autologous marrow to determine the following:

  • whether the source of relapse after BMT for AML is residual malignant cells in the harvested marrow or in the patient, and whether marrow purging is therefore rational.
  • whether the majority of AML, which lack genetic markers, represent abnormalities in a multi-lineage progenitor cell, and whether therefore, auto grafting/intensified chemotherapy is ever likely to augment the cure rate.
  • the mechanisms of autologous reconstitution, and the effects of stimuli which modify the process.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged between 1 and 18 years at diagnosis with acute nonlymphocytic leukemia in first remission are eligible for this protocol.
  • Patients enrolled on the AML-87 study in second or subsequent remission are eligible for this protocol.

Exclusion criteria

  • Has an HLA-matched, MLC-compatible donor(unless parents and/or patient refuses transplant.
  • Diagnosis of FAB M3 or FAB M3v (acute progranulocytic leukemia)
  • Life expectancy limited by disease other than leukemia
  • Significant cardiac disease (echo shortening fraction <25% or MUGA scan <50%)
  • Severe renal dysfunction, i.e., creatinine clearance less than 60cc/1.73 m2/min
  • Severe restrictive pulmonary disease (FCV less than 40% of predicted)
  • Severe hepatic disease (bilirubin greater than 3 mg/dl or SGPT greater than 500IU)
  • Severe personality disorder or mental illness
  • Previous severe cystitis from cyclophosphamide
  • Previous total dose of anthracyclines of >450 mg/m2
  • Sever infection that on evaluation by the PI precludes ablative chemotherapy or successful transplantation
  • Previous autologous transplant
  • HIV reactivity
  • Karnofsky score <70%

Treatment and study plan

busulfan

Drug

See Detailed Description section for description of treatment plan.

Other names: Myleran

Cyclophosphamide

Drug

See Detailed Description section for description of treatment plan.

Other names: Cytoxan, CTX

Mesna

Drug

See Detailed Description section for description of treatment plan.

Other names: MESNCX

Primary outcomes

  1. To estimate the continuous complete remission rate at 2 years for children with AML in first complete remission treated with Autologous Bone Marrow Transplant (ABMT).

    Time frame: 2 years post transplant

Sponsors and collaborators

Lead sponsor

St. Jude Children's Research Hospital

Other

Registry information

Official study title

Autologous Bone Marrow Transplant for Children With AML in First Complete Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse

Important dates

Study start
1991
Primary completion
1995
Study completion
2008
First posted
Apr 28, 2008
Registry last updated
Apr 28, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.